CASI - Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Deals and Financings
InventisBio of Shanghai closed a $70 million Series C financing co-led by Advantech Capital and CMBI, followed by Pudong Innotek (see story). Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases. The company has close to 30 programs in development, including two under China NDA review. Previously, InventisBio raised $25 million in two venture rounds led by Lilly Asia Venture and OrbiMed Asia, which both participated in the C round.
BGI Genomics (SHZ:300696) of Shenzhen formed a $50 million partnership with US-based Natera (NTRA)